AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

VALIRX PLC

AGM Information Jul 23, 2020

7998_dva_2020-07-23_244ad85b-db78-4993-a631-8489c69becd0.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 9216T

ValiRx PLC

23 July 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Result of AGM

ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The proxy votes are set out below:-

Resolutions For Against Discretion
Resolution 1 - Receive the annual report and accounts 4,612,178 0 2,000
Resolution 2 - Re-appoint Gerry Desler as a director 4,226,311 377,739 2,000
Resolution 3 - Re-appoint Dr Suzanne Dilly as a director 4,579,542 23,437 2,000
Resolution 4 - Re-appoint Martin Lampshire as a director 4,579,542 24,623 2,000
Resolution 5 - Re-appoint Dr Kevin Cox as a director 4,580,958 23,207 2,000
Resolution 6 - Re-appoint the auditors 4,573,342 26,058 2,000
Resolution 7 - Set the auditors' remuneration 4,548,033 49,943 2,000
Resolution 8 - Provide authority to allot share capital 4,441,339 62,857 2,008
Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution) 4,436,339 67,857 2,008

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

ValiRx plc Tel: +44 (0) 20 7073 2628

www.valirx.com
Suzanne Dilly [email protected]
Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker
Tel: +44 (0) 20 7469 0930

Notes for Editors

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.  We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGSEDFFDESSEIW

Talk to a Data Expert

Have a question? We'll get back to you promptly.